Evidence map›Paper›PMID 36139396›Full record

ArticleCells2022

Decreased Expression of Sam68 Is Associated with Insulin Resistance in Granulosa Cells from PCOS Patients.

Teresa Vilariño-García, Pilar Guadix, Mónica Dorado-Silva, Pascual Sánchez-Martín, Antonio Pérez-Pérez, Víctor Sánchez-Margalet

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Role of Sam68 in different types of cancer (Review).International journal of molecular medicine · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Teresa Vilariño-GarcíaDepartment of Medical Biochemistry and Molecular Biology and Immunology, Virgen Macarena University Hospital, School of Medicine, University of Seville, 41009 Seville, Spain.
Pilar GuadixObstetrics and Gynecology Department, Virgen Macarena University Hospital, School of Medicine, University of Seville, 41009 Seville, Spain.
Mónica Dorado-SilvaGINEMED, Assisted Reproduction Centre, 41010 Seville, Spain.
Pascual Sánchez-MartínGINEMED, Assisted Reproduction Centre, 41010 Seville, Spain.
Antonio Pérez-PérezDepartment of Medical Biochemistry and Molecular Biology and Immunology, Virgen Macarena University Hospital, School of Medicine, University of Seville, 41009 Seville, Spain.ORCID 0000-0002-5660-735X
Víctor Sánchez-MargaletDepartment of Medical Biochemistry and Molecular Biology and Immunology, Virgen Macarena University Hospital, School of Medicine, University of Seville, 41009 Seville, Spain.ORCID 0000-0001-8638-8680
Hospital Universitario Virgen Macarena · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivePolycystic ovary syndrome (PCOS) is a complex metabolic disorder associated with ovulatory dysfunction, hyperandrogenism, obesity, and insulin resistance, which leads to subfertility. PCOS is the most frequent metabolic disorder in women and the major cause of infertility. Susceptibility to developing PCOS is determined by a complex interaction between environmental and genetic factors. Although different mechanisms have been proposed to explain PCOS manifestations, defects in insulin actions or in the insulin signaling pathways are central in the pathogenesis of the syndrome. However, the mechanisms (molecular players and signaling pathways) underlying its primary origin still remain an unsolved issue. Current research is increasingly focusing on the discovery of novel biomarkers to further elucidate the complex pathophysiology of PCOS. Sam68, an RNA-binding protein, is recruited to insulin signaling, mediating different insulin actions. We aimed to investigate the role of Sam68 in insulin signaling and the possible implications of Sam68 in the insulin resistance in PCOS. MATERIALS AND

methodsGranulosa cells were taken from women with PCOS (n = 25) and healthy donors (n = 25) and, within the age range of 20 to 42 years, from GINEMED, Assisted Reproduction Centre, Seville, Spain. The Sam68 expression level was analyzed both by qPCR and immunoblot. Statistical significance was assessed by one-way ANOVA, followed by a post-hoc test. A

resultsWe found that insulin stimulation increases the phosphorylation and expression level of Sam68 in granulosa cells from normal donors. The downregulation of Sam68 expression resulted in a lower activation of both the MAPK and the PI3K pathways in response to insulin. Moreover, the granulosa cells from the women with PCOS presented a lower expression of Sam68, as well as insulin receptor and insulin receptor substrate-1 (IRS-1). In these cells, the overexpression of Sam68 resulted in an increased activation of both the MAPK and the PI3K pathways in response to insulin.

conclusionsThese results suggest the participation of Sam68 in insulin receptor signaling, mediating the insulin effect in granulosa cells, and they suggest the possible role of Sam68 in the insulin resistance of PCOS.

Indexed as

Adaptor Proteins, Signal TransducingDNA-Binding ProteinsInsulin ResistancePolycystic Ovary SyndromeRNA-Binding ProteinsAdultFemaleGranulosa CellsHumansInsulinInsulin Receptor Substrate ProteinsPhosphatidylinositol 3-KinasesReceptor, InsulinYoung AdultAdaptor Proteins, Signal TransducingDNA-Binding ProteinsInsulinInsulin Receptor Substrate ProteinsKHDRBS1 protein, humanPhosphatidylinositol 3-KinasesReceptor, InsulinRNA-Binding Proteinsinsulinpolycystic ovary syndrome (PCOS)Sam68signaling pathways

Identifiers

PMID36139396
PMCPMC9496917
OpenAlexW4295592656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.